ClinicalTrials.Veeva

Menu

Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

N

Nova Scotia Health Authority (NSHA)

Status

Withdrawn

Conditions

Adrenergic Pathology

Treatments

Drug: Administration of 123Iodine MIBG

Study type

Observational

Funder types

Other

Identifiers

NCT01912040
123Iodine MIBG

Details and patient eligibility

About

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Full description

We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Sex

All

Ages

1+ month old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with potential Adrenergic pathology

Exclusion criteria

  • Pregnant or breast feeding females
  • Hypersensitivity to MIBG

Trial design

0 participants in 1 patient group

Patients
Description:
Administration of 123Iodine MIBG to the patients referred .
Treatment:
Drug: Administration of 123Iodine MIBG

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems